TorreyPines merged with Axonyx Inc. on October 3, 2006. The Company's financial statements reflect the historical results of TorreyPines prior to the merger and that of the combined company following the merger, and do not include the historical results of Axonyx Inc. prior to the completion of the merger.
About TorreyPines Therapeutics, Inc.
TorreyPines Therapeutics, Inc. is a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel small molecules to treat diseases and disorders of the central nervous system (CNS). Led by an accomplished management team, TorreyPines is leveraging novel drug targets and technologies to potentially deliver new CNS therapies for chronic pain, including migraine and neuropathic pain; and cognitive disorders, including cognitive impairment associated with schizophrenia and Alzheimer's disease. Further information is available at http://www.torreypinestherapeutics.com.
This press release contains forward-looking statements or predictions.
Such forward-looking statements include, but are not limited to, statements
regarding the potential for tezampanel as a treatment for migraine, the
potential timing, development and initiation of Phase III clinical trials
of tezampanel, the potential for NGX267 to treat the symptoms of cognitive
impairment associated with schizophrenia and the potential for NGX267 to
treat dry mouth, or xerostomia. Such statements are subject to numerous
known and unknown risks, uncertainties and other factors, which may cause
|SOURCE TorreyPines Therapeutics, Inc.|
Copyright©2007 PR Newswire.
All rights reserved